Unión Europea - español - EMA (European Medicines Agency)

ceva santé animale - influenza a virus/human strain: a/jena/vi5258/2009 (h1n1)pdm09, inactivated - inmunológicos, vacunas virales inactivadas para cerdos, virus de la gripe porcina - cerdos - inmunización activa de cerdos desde la edad de 8 semanas en adelante contra el virus de influenza porcina h1n1 pandémica para reducir la carga pulmonar viral y la excreción viral. the vaccine can be used during pregnancy up to three weeks before expected farrowing and during lactation lactation.

Unión Europea - español - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - cerdos - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Unión Europea - español - EMA (European Medicines Agency)

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inactivado virales y bacterianas inactivadas vacunas - cerdos - para la inmunización activa de cerdos desde las 3 semanas de edad contra el circovirus porcino tipo 2 (pcv2) para reducir la carga viral en sangre y tejidos linfoides y la excreción fecal causada por la infección con pcv2. para la inmunización activa de cerdos mayores de 3 semanas contra mycoplasma hyopneumoniae para reducir las lesiones pulmonares causadas por la infección con m. hyopneumoniae.

Unión Europea - español - EMA (European Medicines Agency)

intervet international b.v. - antígeno de la subunidad orf2 del circovirus porcino tipo 2 - immunologicals for suidae, inactivated viral vaccines - cerdos - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by pcv2 infection.  to reduce loss of daily weight gain and mortality associated with pcv2 infection.

Unión Europea - español - EMA (European Medicines Agency)

zoetis belgium sa - circovirus porcino vacuna inactivada, recombinante) - immunologicals for suidae, inactivated viral vaccines - los cerdos (de engorde) - para la inmunización activa de cerdos desde las 3 semanas de edad contra el circovirus porcino tipo 2 (pcv2) para reducir la carga viral en sangre y tejidos linfoides y la excreción fecal causada por la infección con pcv2.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

implantes europeos s.a.c. -

Unión Europea - español - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - proteína orf2 del circovirus porcino tipo 2 - inmunológicos para suidos - cerdos - para la inmunización activa de cerdos sin pcv2 anticuerpos derivados de la madre desde la edad de 2 semanas frente a circovirus porcino tipo 2 (pcv2),.

Unión Europea - español - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - parvovirus porcino, la cepa de la 27a, proteína viral 2 - inmunológicos para suidos - cerdos - para la inmunización activa de hembras y primerizas a partir de los 5 meses de edad para proteger a la progenie contra transplacentaria de la infección causada por el parvovirus porcino.

Unión Europea - español - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - inmunológicos para suidos - los cerdos (de engorde) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Argentina - español - SANI (Asociación de Cooperativas Argentinas)

elanco animal health - bacterina escherichia coli y clostridium perfringens tipo c - bacterina escherichia coli y clostridium perfringens tipo c - porcinos